Cure My Disease

Don't miss your cure!

 Log in / Sign up

Your feelings and blood work could predict cancer treatment outcomes

NCT ID NCT06629714

Knowledge-focused Sponsor: Anhui Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study followed 196 people with advanced lung or stomach cancer who had not yet received treatment. Researchers wanted to see if emotional distress before starting immunotherapy, along with certain blood markers of inflammation and metabolism, could predict how long patients lived without their cancer getting worse. The goal was to find simple, non-invasive ways to better understand who might benefit most from immunotherapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

196 people

The number who actually took part.

Started

Oct 2020

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Cohort 1 comprises patients diagnosed with treatment-naïve, advanced and inoperable Gastroesophageal Cancer (GEC), encompassing those with esophageal cancer, gastric cancer, and gastroesophageal junction cancer who are undergoing first-line ICI therapy. Cohort 2 consists of patients with treatment-naïve, advanced and inoperable Non-Small Cell Lung Cancer (NSCLC) receiving first-line ICI therapy.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Cohort 1 \& 2 Inclusion Criteria: * Meet the diagnostic criteria for cancer (including esophageal, gastric, GEJ or NSCLC) through clinical, pathological, and imaging examinations; * Karnofsky Performance Status (KPS) score should be equal to or greater than 80 points; * Unresectable locally advanced or metastatic; * Systematic treatments naive ( e. g., chemotherapy, anti-angiogenic drugs, targeted drugs, and immunotherapy); * Presence of at least one measurable lesion according to the Response Evaluation Criteria in Advanced Solid Tumors version 1.1 (RECIST v1.1); * Receiving PD-1/PD-L1 inhibitors monotherapy or combination with chemotherapy; * Informed and agreed to participate in the study; * Required to complete the questionnaire independently or with assistance from others if needed; * Legal age, 18 years or older. Exclusion Criteria: * Oncogene-driver positive; * Combined with other malignant tumors in the past 3 years; * Concurrent acute or chronic psychiatric disorders; * Current receiving anti-depressive or anti-anxiety therapy or other psychotropic drugs; * Previous treatment with other clinical drug trials; * Patients with symptomatic brain metastasis; * Severe intellectual disabilities or other communication difficulties that hindered normal interaction.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Biomarkers / blood are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal cancer Inflammation inflammatory disease Neoplasms, Second Primary non-small cell lung carcinoma secondary malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Biomarkers / blood Cancer, treatment-related Emotional distress Gastroesophageal cancer (GC) Immune checkpoint inhibitors Inflammation Non-small cell lung cancer Progression free survival(PFS)

Contacts and locations

Locations

  • Second Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.